VRTXVertex Pharmaceuticals
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. 10-K, Item 1
- Employees
- 6,400
- Headquarters
- Boston, MA
- CEO
- Reshma Kewalramani
- Next results
- around Feb 11, 2027
The numbers VRTX said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.
Of 2 range targets with a reported result: 2 came in above the last range given, 0 within it, 0 below it.
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Revenue Fiscal 2026 |
Given $12.95B to $13.10B release 2026-02-12
Raised $13.10B to $13.20B release 2026-08-03
Raised $13.15B to $13.25B release 2026-11-02
|
– | Not reported yet |
The company's words— Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribu te $500 million or more in reve nue — release 2026-02-12 Vertex today raised its full year 2026 total revenue guidance to $13.1 billion to $13.2 billion from $12.95 billion to $13.1 billion previously. release 2026-08-03 Vertex today raised its full year 2026 total revenue guidance to $13.15 billion to $13.25 billion from $13.1 billion to $13.2 billion previously. release 2026-11-02 | |||
| Revenue Fiscal 2025 (ended 2025-12-31) |
Given $11.75B to $12.00B release 2025-02-10
Raised $11.85B to $12.00B release 2025-05-05
Raised $11.90B to $12.00B release 2025-11-03
|
$12.00B 10-K filed 2026-02-13 |
Above the range |
The company's words— Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion — release 2025-02-10 Vertex today raised the low end of its full-year 2025 revenue guidance range from $11.75 to $12 billion to $11.85 billion to $12 billion, which assumes continued growth in CF, including the launch of ALYFTREK; as well as continued uptake of CASGEVY in multiple regions; and early contributions from the launch of JOURNAVX. release 2025-05-05 Vertex today refined its full year 2025 revenue guidance with total revenue now expected to be $11.9 to $12.0 billion, which assumes continued growth in CF, including the global launch of ALYFTREK; continued uptake of CASGEVY in multiple regions; and early contributions from the U.S. launch of JOURNAVX. release 2025-11-03 | |||
| Revenue Fiscal 2024 (ended 2024-12-31) |
Given $10.55B to $10.75B release 2024-02-05
Raised $10.65B to $10.85B release 2024-08-01
Raised $10.80B to $10.90B release 2024-11-04
|
$11.02B 10-K filed 2025-02-13 |
Above the range |
The company's words— Company provides full year 2024 product revenue guidance of $10.55 to $10.75 billion — release 2024-02-05 Full Year 2024 Financial Guidance … Vertex today raised its full year product revenue guidance from $10.55-$10.75 billion to $10.65-$10.85 billion. release 2024-08-01 Vertex today raised its full-year 2024 product revenue guidance from $10.65 billion to $10.85 billion to $10.8 billion to $10.9 billion. release 2024-11-04 | |||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (13 releases since 2023-11-06), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Work on VRTX in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/VRTX/export.csv") into a cell.